Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for AMGEN INC., a global biotechnology company, for the period ended March 31, 2000. The financial statements are unaudited but include all normal recurring accruals. The Company primarily discovers, develops, manufactures, and markets human therapeutics, with key products including EPOGEN(R) and NEUPOGEN(R).
Key Financial Metrics
| Metric (in millions) | Q1 2000 | Q1 1999 |
|---|---|---|
| Total Revenues | $814.1 | $745.5 |
| Net Income | $266.2 | $247.2 |
| Operating Income | $352.5 | $329.4 |
| Cash from Operations | $294.3 | $200.7 |
| Cash & Equivalents | $125.8 | $114.1 |
| Marketable Securities | $1,353.8 | $1,202.1 |
| Long-term Debt | $223.0 | $223.0 |
| Commercial Paper | $99.8 | $99.5 |
| Earnings Per Share (Diluted) | $0.25 | $0.23 |
Margins: Cost of sales as a percentage of product sales decreased to 12.3% in Q1 2000 from 13.4% in Q1 1999. The effective tax rate was 30.8% compared to 28.5% in the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 9.2% to $814.1 million. Product sales rose slightly by 1.4% ($697.6M vs $688.3M), while corporate partner revenues surged 175% to $74.2 million, driven by a payment from Kirin-Amgen, Inc.
- Product Performance: EPOGEN(R) sales increased 12% to $440.4 million due to higher demand, though impacted by inventory drawdowns. NEUPOGEN(R) sales decreased 13% to $250 million due to wholesaler inventory effects and a stronger U.S. dollar.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 28% to $169.7 million due to staff costs and marketing for new product launches. Loss of affiliates, net, increased significantly to $16.4 million.
- Cash Flow: Net cash provided by operating activities increased 46.6% to $294.3 million, primarily due to improvements in trade receivables.
- Capital Allocation: The Company repurchased 3.5 million shares of common stock for $225.1 million. Capital expenditures were $92.5 million.
Guidance, Outlook, and Risks
- 2000 Guidance: Amgen expects total product sales growth in the high single digits. Earnings per share for 2000 are projected to be in the range of $1.06 to $1.08.
- Product Outlook: EPOGEN(R) sales growth is expected to be in the low teens. NEUPOGEN(R) sales growth is expected to be in the mid-single digits.
- Regulatory Risks: The Company notes potential impacts from proposed Medicare reimbursement cuts for EPOGEN(R) (10% cut proposed) and changes to the reimbursement basis for NEUPOGEN(R) (reduction from 95% to 83% of AWP) in the Clinton administration's fiscal year 2001 budget.
- Legal Contingencies: Significant ongoing arbitration with Johnson & Johnson regarding Epoetin alfa sales methodology and "spillover" sales. Amgen was awarded approximately $77.5 million in costs and expenses, though J&J has petitioned to vacate this award. Amgen has also filed a demand to terminate J&J's license rights based on alleged breach.
- Other Litigation: Pending trials regarding patent disputes with Genentech (scheduled Dec 2000) and Transkaryotic Therapies/Aventis S.A. (scheduled May 2000).
Investor Verification Checklist
- Verify the impact of the proposed Medicare reimbursement cuts on EPOGEN(R) and NEUPOGEN(R) sales volumes and pricing.
- Monitor the status of the Johnson & Johnson arbitration, specifically the petition to vacate the $77.5 million cost award and the trial regarding license termination.
- Assess the sustainability of the 175% increase in corporate partner revenues, which was driven by a one-time payment from Kirin-Amgen.
- Review the Company's ability to maintain high single-digit sales growth given the inventory drawdowns and wholesaler effects noted in Q1 2000.
- Track the progress of patent litigation against Genentech and Transkaryotic Therapies/Aventis S.A.